đŸ“Ŗ In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).

â–ļī¸ 𝐕đĸ𝐞𝐰 𝐅𝐮đĨđĨ 𝐑𝐞𝐩𝐨đĢ𝐭 𝐰đĸ𝐭𝐡 𝐋𝐚𝐭𝐞đŦ𝐭 𝐈𝐧đŦđĸ𝐠𝐡𝐭đŦ:- https://www.marknteladvisors.c....om/research-library/

#prostate_cancer_market #prostatecancer #cancer #biopharma #ultrasound #tumor #healthcare #marknteladvisors #marketresearch

image